التفاصيل البيبلوغرافية
| العنوان: |
Infigratinib versus placebo in patients with resected urothelial cancer (UC) bearing FGFR3 mutation or fusion: Primary DFS analysis from the phase 3, randomized PROOF302 study. |
| المؤلفون: |
Pal, Sumanta Kumar, Grivas, Petros, Gupta, Shilpa, Valderrama, Begoña Pérez, Rodriguez-Vida, Alejo, Roghmann, Florian, Sevillano, Elena, Matin, Surena F., Loriot, Yohann, Sridhar, Srikala S., Sonpavde, Guru P., Fleming, Mark T., Lerner, Seth P., Bellmunt, Joaquim, Master, Viraj A., Tripathi, Abhishek, Davis, Kim, Van Veenhuyzen, David Friedrich, Weng, Richard, Daneshmand, Siamak |
| المصدر: |
Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p629-629, 193p |
| قاعدة البيانات: |
Supplemental Index |
